China approves two-dose schedule for GSK's cervical cancer drug
GSK
1,773.50p
16:40 08/05/24
0.71%
12.50p
UK pharma giant GSK said China's National Medical Products Administration has approved a two-dose vaccine schedule for its Cervarix treatment in girls aged between 9 to 14 years for the prevention of cervical cancer.
FTSE 100
8,354.05
16:50 08/05/24
n/a
n/a
FTSE 350
4,592.23
16:39 08/05/24
n/a
n/a
FTSE All-Share
4,544.24
16:54 08/05/24
n/a
n/a
Pharmaceuticals & Biotechnology
23,505.36
16:40 08/05/24
1.01%
234.05
In 2020, there were approximately 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, GSK said on Friday.